Osimertinib and aspirin before surgery for EGFR-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining osimertinib (a targeted pill) with aspirin before surgery for people with stage II to IIIA lung adenocarcinoma that has an EGFR mutation. The goal is to see if this combination shrinks tumors and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II to IIIA lung adenocarcinoma that can be removed with surgery.
- Your tumor has an EGFR mutation called Ex19del or L858R.
- You are well enough to be up and about (ECOG performance status 0 or 1).
- Your main tumor is at least 1 centimeter in size.
- You haven't had other cancer treatments for this lung cancer before.
- You are not currently taking blood thinners (other than aspirin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
This trial tests if removing the main lung tumor followed by the targeted therapy osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer. It is for those who have not had prior treatment and are healthy enough for surgery.
This trial tests whether using a blood test (ctDNA) to guide targeted therapy after surgery can improve outcomes for patients with stage II-IIIA non-small cell lung cancer that has an EGFR mutation. If you qualify, you may receive a targeted pill (osimertinib) based on your ctDNA results.
This trial tests whether adding SYS6010 to osimertinib before surgery works better than osimertinib alone for people with a type of lung cancer that has an EGFR mutation. The goal is to shrink the tumor and improve surgery outcomes.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.